N-((2R,3S)-2-(4-Chlorophenyl)-1-(1,4-dimethyl-2-oxo-1,2-dihydroquinolin-7-yl)-6-oxopiperidin-3

LP99 is a novel BRD7 and BRD9 specific inhibitor.

LP99 is a potent and selective bromodomain BRD9 and BRD7 inhibitor with a higher potency for BRD9 (Kd = 99 nM) than for BRD7 (Kd = 909 nM), and no inhibition for any of the 48 other BRDs tested. LP99 was shown to disrupt BRD7 and BRD9 binding to chromatin in cells. LP99 also inhibited interleukin 6 (IL-6) secretion, suggesting that BRD7/9 plays a role in the regulation of pro-inflammatory cytokine secretion. LP99 is not cell cytotoxic up to 25 μM. For full characterization details, please visit the LP99 probe summary on the Structural Genomics Consortium (SGC) website.To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc

Store at -20°C